Skip to main content

Table 3 Effect of SGLT2 inhibitors on clinical outcomes among participants with moderate or severe albuminuria

From: Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis

Outcome No. studies No. events Sample size HR (95% CI) I2, % PHeterogeneity PEgger test
Overall        
 MACE 4 1284* 17,084 0.80 (0.71–0.90) 25.6 0.234 0.683
 Kidney composite 4 1124* 17,208 0.66 (0.58–0.75) 1.4 0.407 0.530
 HHF 4 670 13,456 0.61 (0.52–0.71) 0.0 0.916 0.791
 Cardiovascular death 3 642 10,209 0.70 (0.55–0.88) 50.9 0.086 0.378
 Fatal and nonfatal MI 3 503 10,209 0.89 (0.75–1.07) 0.0 0.679 0.355
 Fatal and nonfatal stroke 3 382 10,209 0.92 (0.75–1.14) 0.0 0.457 0.279
 All-cause mortality 4 817* 13,115 0.76 (0.66–0.88) 28.8 0.219 0.285
Moderate albuminuria        
 MACE 3 520* 7868 0.92 (0.79–1.07) 0.0 0.795 0.342
 Kidney composite 2 70* 5855 0.98 (0.62–1.57) 0.0 0.962 NA
 HHF 3 261 6771 0.60 (0.47–0.77) 0.0 0.473 0.283
 Cardiovascular death 2 229 4279 0.70 (0.35–1.38) 84.2 0.012 NA
 Fatal and nonfatal MI 2 233 4279 1.01 (0.77–1.32) 0.0 0.774 NA
Fatal and nonfatal stroke 2 153 4279 1.06 (0.76–1.48) 0.0 0.363 NA
 All-cause mortality 2 147* 4279 0.78 (0.47–1.28) 80.4 0.024 NA
Severe Albuminuria        
 MACE 4 764* 9216 0.73 (0.65–0.83) 0.0 0.444 0.428
 Kidney composite 3 673* 8447 0.63 (0.53–0.76) 0.8 0.365 0.729
 HHF 4 409 6685 0.62 (0.51–0.75) 0.0 0.915 0.815
 Cardiovascular death 3 413 5930 0.72 (0.59–0.87) 0.0 0.408 0.348
 Fatal and nonfatal MI 3 270 5930 0.81 (0.64–1.03) 0.0 0.654 0.389
 Fatal and nonfatal stroke 3 229 5930 0.85 (0.65–1.11) 0.0 0.410 NA
 All-cause mortality 3 473* 5930 0.77 (0.65–0.90) 0.0 0.415 0.234
  1. *The number of MACE and kidney composite outcomes were not reported in SCORED and are therefore not included in the table. Likewise, the number of all-cause deaths by albuminuria were not reported in the CANVAS program and are not included in the table. CANVAS indicates Canagliflozin Cardiovascular Assessment Study, CI confidence interval; HHF hospitalization for heart failure, MACE major adverse cardiovascular events, HR hazard ratio, MI myocardial infarction, NA not applicable, NR not reported, SCORED Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk, SGLT2 sodium-glucose cotransporter 2